Eli Lilly and Company (NYSE:LLY) Price Target Raised to $1,001.00

Eli Lilly and Company (NYSE:LLY) had its price target hoisted by BMO Capital Markets from $900.00 to $1,001.00 in a report released on Wednesday, Benzinga reports. BMO Capital Markets currently has an outperform rating on the stock.

Several other research firms have also recently issued reports on LLY. The Goldman Sachs Group increased their target price on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a neutral rating in a research note on Thursday, April 11th. Morgan Stanley increased their target price on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an overweight rating in a research note on Friday, February 16th. Wells Fargo & Company increased their target price on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the stock an overweight rating in a research note on Tuesday, February 6th. DZ Bank cut shares of Eli Lilly and Company from a buy rating to a hold rating and set a $820.00 target price on the stock. in a research note on Wednesday, February 21st. Finally, Bank of America increased their target price on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a buy rating in a research note on Friday, March 1st. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of Moderate Buy and an average price target of $757.95.

Eli Lilly and Company Stock Down 2.8 %

LLY opened at $734.97 on Wednesday. The company has a 50 day moving average of $761.75 and a 200 day moving average of $670.56. The company has a market cap of $698.52 billion, a PE ratio of 108.24, a price-to-earnings-growth ratio of 1.50 and a beta of 0.37. Eli Lilly and Company has a 12 month low of $419.80 and a 12 month high of $800.78. The company has a current ratio of 1.35, a quick ratio of 0.73 and a debt-to-equity ratio of 1.90.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Tuesday, April 30th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.53 by $0.05. The company had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. Eli Lilly and Company’s revenue for the quarter was up 26.0% on a year-over-year basis. During the same period last year, the firm earned $1.62 EPS. On average, sell-side analysts expect that Eli Lilly and Company will post 13.83 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Lipe & Dalton bought a new position in Eli Lilly and Company in the 4th quarter valued at approximately $26,000. Thompson Investment Management Inc. bought a new stake in shares of Eli Lilly and Company in the 3rd quarter worth $27,000. Tidemark LLC purchased a new position in shares of Eli Lilly and Company in the fourth quarter worth $29,000. Core Wealth Advisors Inc. lifted its holdings in shares of Eli Lilly and Company by 188.2% during the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after purchasing an additional 32 shares in the last quarter. Finally, Legacy Financial Group LLC bought a new position in shares of Eli Lilly and Company during the third quarter valued at $35,000. Institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.